# Novo Stock's 10-Year Outlook

> Novo Nordisk's diabetes and weight loss drugs could drive strong returns over the next decade despite patent expiries and competition.
- Title: Novo Stock's 10-Year Outlook · The Motley Fool | Shortify
- Summary: Novo Nordisk's diabetes and weight loss drugs could drive strong returns over the next decade despite patent expiries and competition. Novo Nordisk may…
- Keywords: novo nordisk, diabetes, weight loss, pharmaceuticals, stock, dividends, patents, cagrisema, ozempic, wegovy, rybelsus, finance
- Source: The Motley Fool — https://fool.com/investing/2026/10/21/where-will-novo-stock-be-in-10-years
- Author: Prosper Junior Bakiny
- Published: 2026-10-21T19:28:00+00:00
- Read time: 1 min
- Topics: novo nordisk, diabetes, weight loss, pharmaceuticals, stock, dividends, patents, cagrisema, ozempic, wegovy, rybelsus, finance
## Novo's Stock Performance
Novo Nordisk stock climbed to an all-time high in 2024 but lost market value over the past two years.
## Core Products Drive Growth
Novo generates sales from diabetes products like Ozempic and Rybelsus, and anti-obesity drugs like Wegovy.
## Patent Expiry Challenge
U.S. patents on Ozempic, Wegovy, and Rybelsus active ingredients expire in 2032, risking cheaper generic competition.
## CagriSema Clinical Progress
Novo races toward CagriSema approval by year-end, combining semaglutide and Cagrilintide for obesity and diabetes treatment.
## CagriSema's Weight Loss Target
CagriSema fell short of the 25% mean weight loss Novo hoped for in head-to-head obesity studies.
## Diversification Strategy
Novo develops products for blood-related disorders and other areas beyond diabetes and weight loss.
## Future Outlook
Novo could deliver competitive returns over the next decade with dividends reinvested and a strong pipeline.
## Key takeaway

Novo Nordisk may deliver competitive returns in 10 years with its diabetes and weight loss pipeline, dividends, and diversified products.